Wednesday, April 3, 2024 Experimental Ebola Vaccines Found Safe and Capable of Producing Immune Responses in Healthy Adults Particles of Ebola virus (Zaire ebolavirus; gold) found both extracellularly and budding from chronically infected African green monkey kidney cells (blue). Image captured at the NIAID Integrated Research Facility in Ft. Detrick, Maryland. Credit: NIAID Ebola news: NIAID researchers evaluated two-dose regimens of experimental Ebola vaccines, finding them safe and capable of producing immune responses in healthy adults in the US and Uganda. Comparisons between the different vaccine regimens revealed important data on how the vaccines could be administered in routine and outbreak settings. The researchers say the experimental vaccines could provide flexibility and choice among Ebola vaccines. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107